Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Luis M. Isola"'
Autor:
Steven Z. Pavletic, Mary M. Horowitz, Daniel J. Weisdorf, John R. Wingard, Leo F. Verdonck, Harry C. Schouten, Stephen R. Spellman, Stella Santarone, Effie W. Petersdorf, Stephanie J. Lee, Thomas R. Klumpp, Madan H. Jagasia, David A. Jacobsohn, Luis M. Isola, Roger Herzig, Robert P. Gale, Mary E. Flowers, Corey S. Cutler, Mitchell S. Cairo, Jean-Yves Y. Cahn, Brian J. Bolwell, Joseph H. Antin, Alvaro Urbano-Ispizua, Michael Hemmer, Anna Hassebroek, John P. Klein, Mukta Arora, Michael Boyiadzis
Supplemental Table 1. Multivariate analysis of late relapse, transplant-related mortality, overall survival after HCT for each disease (AML, ALL, CML, MDS)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a8b6bb0ec143b555d4baa55cd9d07bc
https://doi.org/10.1158/1078-0432.22459019.v1
https://doi.org/10.1158/1078-0432.22459019.v1
Autor:
Steven Z. Pavletic, Mary M. Horowitz, Daniel J. Weisdorf, John R. Wingard, Leo F. Verdonck, Harry C. Schouten, Stephen R. Spellman, Stella Santarone, Effie W. Petersdorf, Stephanie J. Lee, Thomas R. Klumpp, Madan H. Jagasia, David A. Jacobsohn, Luis M. Isola, Roger Herzig, Robert P. Gale, Mary E. Flowers, Corey S. Cutler, Mitchell S. Cairo, Jean-Yves Y. Cahn, Brian J. Bolwell, Joseph H. Antin, Alvaro Urbano-Ispizua, Michael Hemmer, Anna Hassebroek, John P. Klein, Mukta Arora, Michael Boyiadzis
Purpose: Malignancy relapse remains a major obstacle for successful allogeneic hematopoietic cell transplantation (HCT). Chronic graft-versus-host disease (cGVHD) is associated with fewer relapses. However, when studying effects of cGVHD on relapse,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1562e3003d7ce693a7bac43e825778d3
https://doi.org/10.1158/1078-0432.c.6524114.v1
https://doi.org/10.1158/1078-0432.c.6524114.v1
Autor:
Steven Z. Pavletic, Mary M. Horowitz, Daniel J. Weisdorf, John R. Wingard, Leo F. Verdonck, Harry C. Schouten, Stephen R. Spellman, Stella Santarone, Effie W. Petersdorf, Stephanie J. Lee, Thomas R. Klumpp, Madan H. Jagasia, David A. Jacobsohn, Luis M. Isola, Roger Herzig, Robert P. Gale, Mary E. Flowers, Corey S. Cutler, Mitchell S. Cairo, Jean-Yves Y. Cahn, Brian J. Bolwell, Joseph H. Antin, Alvaro Urbano-Ispizua, Michael Hemmer, Anna Hassebroek, John P. Klein, Mukta Arora, Michael Boyiadzis
Supplemental Table 4. Multivariate analysis showing impact of cGVHD characteristics on treatment related mortality, disease free survival, overall survival in patients with AML, ALL, MDS who developed cGVHD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a29a4f89ff9eb180a33441e9c479c0
https://doi.org/10.1158/1078-0432.22459010.v1
https://doi.org/10.1158/1078-0432.22459010.v1
Autor:
Steven Z. Pavletic, Mary M. Horowitz, Daniel J. Weisdorf, John R. Wingard, Leo F. Verdonck, Harry C. Schouten, Stephen R. Spellman, Stella Santarone, Effie W. Petersdorf, Stephanie J. Lee, Thomas R. Klumpp, Madan H. Jagasia, David A. Jacobsohn, Luis M. Isola, Roger Herzig, Robert P. Gale, Mary E. Flowers, Corey S. Cutler, Mitchell S. Cairo, Jean-Yves Y. Cahn, Brian J. Bolwell, Joseph H. Antin, Alvaro Urbano-Ispizua, Michael Hemmer, Anna Hassebroek, John P. Klein, Mukta Arora, Michael Boyiadzis
Supplemental Table 2. Multivariate analysis showing impact of cGVHD characteristics in CML patients on relapse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd075a41ef6607b9609e016590c0139a
https://doi.org/10.1158/1078-0432.22459016
https://doi.org/10.1158/1078-0432.22459016
Autor:
Steven Z. Pavletic, Mary M. Horowitz, Daniel J. Weisdorf, John R. Wingard, Leo F. Verdonck, Harry C. Schouten, Stephen R. Spellman, Stella Santarone, Effie W. Petersdorf, Stephanie J. Lee, Thomas R. Klumpp, Madan H. Jagasia, David A. Jacobsohn, Luis M. Isola, Roger Herzig, Robert P. Gale, Mary E. Flowers, Corey S. Cutler, Mitchell S. Cairo, Jean-Yves Y. Cahn, Brian J. Bolwell, Joseph H. Antin, Alvaro Urbano-Ispizua, Michael Hemmer, Anna Hassebroek, John P. Klein, Mukta Arora, Michael Boyiadzis
Supplemental Table 3. Multivariate analysis showing impact of cGVHD characteristics on treatment related mortality, disease free survival and overall survival in patients with CML who developed cGVHD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17f3f162450909dadf1eee374d2d4530
https://doi.org/10.1158/1078-0432.22459013.v1
https://doi.org/10.1158/1078-0432.22459013.v1
Autor:
Steven Z. Pavletic, Mary M. Horowitz, Daniel J. Weisdorf, John R. Wingard, Leo F. Verdonck, Harry C. Schouten, Stephen R. Spellman, Stella Santarone, Effie W. Petersdorf, Stephanie J. Lee, Thomas R. Klumpp, Madan H. Jagasia, David A. Jacobsohn, Luis M. Isola, Roger Herzig, Robert P. Gale, Mary E. Flowers, Corey S. Cutler, Mitchell S. Cairo, Jean-Yves Y. Cahn, Brian J. Bolwell, Joseph H. Antin, Alvaro Urbano-Ispizua, Michael Hemmer, Anna Hassebroek, John P. Klein, Mukta Arora, Michael Boyiadzis
Supplemental Figure 1. Cumulative incidence of cGVHD, relapse and death in patients with AML, ALL, CML, MDS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ff0a47fd6e908c56333b879a03134c9
https://doi.org/10.1158/1078-0432.22459022.v1
https://doi.org/10.1158/1078-0432.22459022.v1
Publikováno v:
Anti-Cancer Drugs. 27:235-238
Ifosfamide has been shown to be associated with encephalopathy in 10-40% of patients. Although it is a well-documented toxicity associated with ifosfamide therapy, an anecdotal upsurge in its occurrence at our institution prompted us to review ifosfa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8abe1685db027074dd083f23293c489
https://doi.org/10.1097/cad.0000000000000321
https://doi.org/10.1097/cad.0000000000000321
Publikováno v:
Transfusion. 54(5)
The current FDA-approved time interval between plerixafor dosing and apheresis initiation is approximately 11 hours, but this time interval is impractical for most care providers. Few studies have examined mobilization kinetics beyond 11 hours in mul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a34d4cb5df485738a245a3f2ea40d883
https://pubmed.ncbi.nlm.nih.gov/24128272
https://pubmed.ncbi.nlm.nih.gov/24128272
Autor:
Luis M. Isola, John P. Mandeli, Janice L. Gabrilove, Steven M. Fruchtman, Celia L. Grosskreutz, Eileen Scigliano
Publikováno v:
Blood. 104:5225-5225
The addition of rituximab to mobilization regimens does not adversely affect collection of adequate numbers of CD34+ PBSC and may decrease tumor cell contamination. Prior administration of rituximab may sensitize lymphoma cells to chemotherapy, but i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ffb3622b1e931c849e86fc4e07a096e
https://doi.org/10.1182/blood.v104.11.5225.5225
https://doi.org/10.1182/blood.v104.11.5225.5225
Autor:
Patel, Sweta U, Yum, Kendra, Kim, Sara, Isola, Luis M, Scigliano, Eileen, Jakubowski, Rita, Park, Doyun
Publikováno v:
Journal of Oncology Pharmacy Practice; Oct2019, Vol. 25 Issue 7, p1762-1766, 5p, 1 Chart